<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01049009</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00017946</org_study_id>
    <nct_id>NCT01049009</nct_id>
  </id_info>
  <brief_title>The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension</brief_title>
  <official_title>The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      High blood pressure (hypertension) is called the &quot;silent killer&quot; because many people do not
      know they have it, and do not know when it is well controlled. Unfortunately, over time
      uncontrolled hypertension can cause irreversible organ damage that can lead to heart attack,
      stroke, heart failure, and kidney failure. If a person cannot control their blood pressure
      with diet and exercise, doctors often prescribe medications to help control the blood
      pressure. Nebivolol is a medication that has been recently approved by the FDA for the
      treatment of hypertension. Our study will investigate whether treatment with nebivolol, as
      compared to another medication called metoprolol, in African Americans with hypertension will
      be more effective in protecting blood vessels against the harmful effects of high blood
      pressure.

      Over time high blood pressure causes hardening of the arteries (atherosclerosis) which leads
      to narrowing of the blood vessels and reduces blood flow to our organs. Arteries also relax
      and contract naturally, which further changes the blood supply. When arteries are narrowed,
      exercise can bring on a condition in which the blood supply is inadequate, and this might
      result in the sensation of pain.

      Cells lining our blood vessels produce a variety of substances that normally cause arteries
      to relax. Two of these substances are called nitric oxide (NO) and endothelium-derived
      hyperpolarizing factor (EDHF). We are trying to determine the nature of these substances in
      African Americans with high blood pressure and how it is affected by nebivolol and
      metoprolol. One way to determine this is to inject drugs such as L-NMMA
      (N(G)-monomethyl-L-arginine) or TEA (tetraethylammonium chloride), which block the production
      of NO and EDHF respectively, and then study what happens to the blood flow at rest and during
      exercise. It is our thought that nebivolol, in comparison to metoprolol, will increase the
      substances that naturally cause arteries to relax and improve blood supply.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial Function Measured by Forearm Blood Flow (FBF) at 12 Weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Forearm blood flow measured by venous occlusion plethysmography at rest, after administration of N(G)-monomethyl-L-arginine (L-NMMA) and tetraethylammonium chloride (TEA), after administration of L-NMMA, TEA, and acetylcholine, and after administration of L-NMMA, TEA, and exercise. Unit of Measure refers to volume of blood (mL) per 100 mL of forearm tissue per minute.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endothelial Function Measured by Forearm Blood Flow (FBF) at 24 Weeks</measure>
    <time_frame>24 weeks</time_frame>
    <description>Forearm blood flow measured by venous occlusion plethysmography at rest, after administration of N(G)-monomethyl-L-arginine (L-NMMA) and tetraethylammonium chloride (TEA), after administration of L-NMMA, TEA, and acetylcholine, and after administration of L-NMMA, TEA, and exercise. Unit of Measure refers to volume of blood (mL) per 100 mL of forearm tissue per minute.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>High Blood Pressure</condition>
  <arm_group>
    <arm_group_label>Nebivolol followed by Metoprolol XL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects are randomized to Nebivolol 5mg and titrate to Nebivolol 10mg two weeks after drug initiation. Ten weeks after titration subjects will cross over to Metoprolol XL 50mg and titrate to Metoprolol XL 100mg two weeks after cross over.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metoprolol XL followed by Nebivolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects are randomized to Metoprolol XL 50mg and titrate to Metoprolol XL 100mg two weeks after drug initiation. Ten weeks after titration subjects will cross over to Nebivolol 5mg and titrate to Nebivolol 10mg two weeks after cross over.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebivolol</intervention_name>
    <description>Subjects will be randomized to either nebivolol or metoprolol xl, and remain on the study drug for 10 weeks. They will then &quot;cross over&quot; to take 10 weeks of the comparator drug.</description>
    <arm_group_label>Nebivolol followed by Metoprolol XL</arm_group_label>
    <arm_group_label>Metoprolol XL followed by Nebivolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol XL</intervention_name>
    <description>Subjects will be randomized to either nebivolol or metoprolol xl, and remain on the study drug for 10 weeks. They will then &quot;cross over&quot; to take 10 weeks of the comparator drug.</description>
    <arm_group_label>Nebivolol followed by Metoprolol XL</arm_group_label>
    <arm_group_label>Metoprolol XL followed by Nebivolol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or post-menopausal females aged 18-80 years.

          -  Subjects self-identified as black or African-American.

          -  Diagnosis of hypertension.

          -  Patients on current anti-hypertensive therapy that does not include beta blockade
             should have BP &gt;135/85.

          -  Patients on anti-hypertensive therapy including beta blockers will have their beta
             blockers discontinued gradually over 2 weeks before enrolment.

          -  Concomitant therapy: Patients will be allowed to be on concomitant therapy with
             aspirin, statins, thiazide diuretics, calcium antagonists (for treatment of
             hypertension), clonidine, or vasodilators. Patients will be on stable medical therapy
             for at least 2 months before recruitment. Patients with previous treatment with beta
             adrenergic blockers (metoprolol, propranolol, atenolol, and labetalol) will also be
             eligible to participate, but will be randomized to the study beta blocker.

        Exclusion Criteria:

          -  Initiation or change in dose of statin or other anti-hypertensive therapy within 2
             months before the study

          -  Inability to return to Emory for follow-up testing

          -  Age &lt; 21 or &gt;80 years

          -  Premenopausal females with potential for pregnancy

          -  Acute infection in previous 2 weeks

          -  On angiotensin antagonists (ACE inhibitors or ARBs)

          -  History of substance abuse

          -  Current neoplasm

          -  Chronic renal failure [creatinine &gt; 2.5 mg/dL] or liver failure (liver enzymes &gt;2X
             normal)

          -  Acute coronary syndrome, Class IV heart failure, CVA, coronary intervention within 2
             months

          -  Known aortic stenosis, hypertrophic cardiomyopathy.

          -  Inability to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Neuman RB, Hayek SS, Poole JC, Rahman A, Menon V, Kavtaradze N, Polhemus D, Veledar E, Lefer DJ, Quyyumi AA. Nitric Oxide Contributes to Vasomotor Tone in Hypertensive African Americans Treated With Nebivolol and Metoprolol. J Clin Hypertens (Greenwich). 2016 Mar;18(3):223-31. doi: 10.1111/jch.12649. Epub 2015 Aug 19.</citation>
    <PMID>26285691</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2010</study_first_submitted>
  <study_first_submitted_qc>January 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2010</study_first_posted>
  <results_first_submitted>December 12, 2014</results_first_submitted>
  <results_first_submitted_qc>December 12, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 19, 2014</results_first_posted>
  <last_update_submitted>March 13, 2017</last_update_submitted>
  <last_update_submitted_qc>March 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Arshed A. Quyyumi</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Nitric Oxide</keyword>
  <keyword>Adrenergic beta-Antagonists</keyword>
  <keyword>Antihypertensive Agents</keyword>
  <keyword>Vasodilator Agents</keyword>
  <keyword>Anti-Arrhythmia Agents</keyword>
  <keyword>Sympatholytics</keyword>
  <keyword>Vascular Resistance</keyword>
  <keyword>Neurotransmitter Agents</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Metoprolol succinate</keyword>
  <keyword>Therapeutic Uses</keyword>
  <keyword>Metoprolol</keyword>
  <keyword>Vascular Diseases</keyword>
  <keyword>Nebivolol</keyword>
  <keyword>Cardiovascular Agents</keyword>
  <keyword>Endothelium-Dependent Relaxing Factors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Nebivolol</mesh_term>
    <mesh_term>Endothelium-Dependent Relaxing Factors</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_id>26285691</doc_id>
      <doc_type>Publication</doc_type>
      <doc_url>https://www.ncbi.nlm.nih.gov/pubmed/26285691</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects recruited from the general medical clinics of The Emory Clinic, Emory University Hospital, and Grady Memorial Hospital between January 2010 through January 2012.</recruitment_details>
      <pre_assignment_details>91 subjects were enrolled but 47 subjects were withdrawn prior to group assignment due to various factors, which included eligibility criteria, lost to follow-up, and withdrawal by subject.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Nebivolol/Metoprolol XL</title>
          <description>Subjects are randomized to Nebivolol 5mg and titrate to Nebivolol 10mg two weeks after drug initiation. Ten weeks after titration subjects will cross over to Metoprolol XL 50mg and titrate to Metoprolol XL 100mg two weeks after cross over.</description>
        </group>
        <group group_id="P2">
          <title>Metoprolol XL/Nebivolol</title>
          <description>Subjects are randomized to Metoprolol XL 50mg and titrate to Metoprolol XL 100mg two weeks after drug initiation. Ten weeks after titration subjects will cross over to Nebivolol 5mg and titrate to Nebivolol 10mg two weeks after cross over.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1 (12 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 2 (12 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline population characteristics only account for subjects that completed the entire study.</population>
      <group_list>
        <group group_id="B1">
          <title>Nebivolol/Metoprolol XL</title>
          <description>Subjects were randomized to Nebivolol 5mg and titrated to Nebivolol 10mg two weeks after drug initiation. Ten weeks after titration, subjects crossed over to Metoprolol XL 50mg and titrated to Metoprolol XL 100mg two weeks after cross over.</description>
        </group>
        <group group_id="B2">
          <title>Metoprolol XL/Nebivolol</title>
          <description>Subjects were randomized to Metoprolol XL 50mg and titrated to Metoprolol XL 100mg two weeks after drug initiation. Ten weeks after titration, subjects crossed over to Nebivolol 5mg and titrated to Nebivolol 10mg two weeks after cross over.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Endothelial Function Measured by Forearm Blood Flow (FBF) at 12 Weeks</title>
        <description>Forearm blood flow measured by venous occlusion plethysmography at rest, after administration of N(G)-monomethyl-L-arginine (L-NMMA) and tetraethylammonium chloride (TEA), after administration of L-NMMA, TEA, and acetylcholine, and after administration of L-NMMA, TEA, and exercise. Unit of Measure refers to volume of blood (mL) per 100 mL of forearm tissue per minute.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol/Metoprolol XL</title>
            <description>Subjects were randomized to Nebivolol 5mg and titrated to Nebivolol 10mg two weeks after drug initiation. Ten weeks after titration, subjects crossed over to Metoprolol XL 50mg and titrated to Metoprolol XL 100mg two weeks after cross over.</description>
          </group>
          <group group_id="O2">
            <title>Metoprolol XL/Nebivolol</title>
            <description>Subjects were randomized to Metoprolol XL 50mg and titrated to Metoprolol XL 100mg two weeks after drug initiation. Ten weeks after titration, subjects crossed over to Nebivolol 5mg and titrated to Nebivolol 10mg two weeks after cross over.</description>
          </group>
        </group_list>
        <measure>
          <title>Endothelial Function Measured by Forearm Blood Flow (FBF) at 12 Weeks</title>
          <description>Forearm blood flow measured by venous occlusion plethysmography at rest, after administration of N(G)-monomethyl-L-arginine (L-NMMA) and tetraethylammonium chloride (TEA), after administration of L-NMMA, TEA, and acetylcholine, and after administration of L-NMMA, TEA, and exercise. Unit of Measure refers to volume of blood (mL) per 100 mL of forearm tissue per minute.</description>
          <units>mL/100 mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At rest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.739" spread="1.365"/>
                    <measurement group_id="O2" value="2.679" spread=".0901"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>L-NMMA+TEA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.963" spread="0.968"/>
                    <measurement group_id="O2" value="2.221" spread="0.630"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>L-NMMA+TEA+ACh</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.376" spread="3.362"/>
                    <measurement group_id="O2" value="7.562" spread="4.358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>L-NMMA+TEA+exercise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.377" spread="2.754"/>
                    <measurement group_id="O2" value="11.574" spread="4.716"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Endothelial Function Measured by Forearm Blood Flow (FBF) at 24 Weeks</title>
        <description>Forearm blood flow measured by venous occlusion plethysmography at rest, after administration of N(G)-monomethyl-L-arginine (L-NMMA) and tetraethylammonium chloride (TEA), after administration of L-NMMA, TEA, and acetylcholine, and after administration of L-NMMA, TEA, and exercise. Unit of Measure refers to volume of blood (mL) per 100 mL of forearm tissue per minute.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol/Metoprolol XL</title>
            <description>Subjects were randomized to Nebivolol 5mg and titrated to Nebivolol 10mg two weeks after drug initiation. Ten weeks after titration, subjects crossed over to Metoprolol XL 50mg and titrated to Metoprolol XL 100mg two weeks after cross over.</description>
          </group>
          <group group_id="O2">
            <title>Metoprolol XL/Nebivolol</title>
            <description>Subjects were randomized to Metoprolol XL 50mg and titrated to Metoprolol XL 100mg two weeks after drug initiation. Ten weeks after titration, subjects crossed over to Nebivolol 5mg and titrated to Nebivolol 10mg two weeks after cross over.</description>
          </group>
        </group_list>
        <measure>
          <title>Endothelial Function Measured by Forearm Blood Flow (FBF) at 24 Weeks</title>
          <description>Forearm blood flow measured by venous occlusion plethysmography at rest, after administration of N(G)-monomethyl-L-arginine (L-NMMA) and tetraethylammonium chloride (TEA), after administration of L-NMMA, TEA, and acetylcholine, and after administration of L-NMMA, TEA, and exercise. Unit of Measure refers to volume of blood (mL) per 100 mL of forearm tissue per minute.</description>
          <units>mL/100 mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At rest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.066" spread="1.469"/>
                    <measurement group_id="O2" value="2.968" spread="1.164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>L-NMMA+TEA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.457" spread="1.549"/>
                    <measurement group_id="O2" value="2.287" spread="0.693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>L-NMMA+TEA+ACh</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.158" spread="4.875"/>
                    <measurement group_id="O2" value="7.534" spread="4.523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>L-NMMA+TEA+exercise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.589" spread="3.550"/>
                    <measurement group_id="O2" value="10.395" spread="2.687"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Only subjects that were randomized into an arm with drug were included in the &quot;at-risk participant&quot; fields.</desc>
      <group_list>
        <group group_id="E1">
          <title>Nebivolol/Metoprolol XL</title>
          <description>Subjects were randomized to Nebivolol 5mg and titrated to Nebivolol 10mg two weeks after drug initiation. Ten weeks after titration, subjects crossed over to Metoprolol XL 50mg and titrated to Metoprolol XL 100mg two weeks after cross over.</description>
        </group>
        <group group_id="E2">
          <title>Metoprolol XL/Nebivolol</title>
          <description>Subjects were randomized to Metoprolol XL 50mg and titrated to Metoprolol XL 100mg two weeks after drug initiation. Ten weeks after titration, subjects crossed over to Nebivolol 5mg and titrated to Nebivolol 10mg two weeks after cross over.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Arshed A. Quyyumi</name_or_title>
      <organization>Emory University School of Medicine</organization>
      <phone>404-727-3655</phone>
      <email>aquyyum@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

